FcGammaRIIB Specific Antibodies and Methods of Use Thereof

Abstract

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

1 . A mouse monoclonal antibody produced by clone 3H7, having ATCC accession number PTA-4592 or an antigen binding fragment thereof. 
     
     
         2 - 3 . (canceled) 
     
     
         4 . A pharmaceutical composition comprising:
 (i.) a therapeutically effective amount of a first antibody that is a chimeric or humanized version of the murine monoclonal antibody produced by clone 3H7, having ATCC accession number PTA-4592, or an antigen binding fragment thereof;   (ii.) a second cytotoxic antibody that specifically binds a cancer antigen; and   (iii.) a pharmaceutically acceptable carrier.   
     
     
         5 - 30 . (canceled) 
     
     
         31 . An isolated antibody, or antigen binding fragment thereof, comprising a light chain variable region and a heavy chain variable region from the murine monoclonal antibody produced by clone 3H7, having ATCC accession number PTA-4592. 
     
     
         32 - 40 . (canceled)